A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
Foretinib (GSK1363089) is an investigational, oral, multikinase inhibitor involved in
invasion, migration, and angiogenesis. This is a phase II, open label, uncontrolled,
parallel, multi-cohort, multicenter 2-stage study to assess the safety and efficacy of
foretinib and erlotinib combination therapy and foretinib monotherapy in genomic
subpopulations of Non-Small-Cell Lung Cancer (NSCLC) subjects.